These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Allogeneic CD3/CD28 cross-linked Th1 memory cells provide potent adjuvant effects for active immunotherapy of leukemia/lymphoma. Har-Noy M; Zeira M; Weiss L; Fingerut E; Or R; Slavin S Leuk Res; 2009 Apr; 33(4):525-38. PubMed ID: 18834631 [TBL] [Abstract][Full Text] [Related]
23. Immunological detection of altered signaling molecules involved in melanoma development. Kawakami Y; Sumimoto H; Fujita T; Matsuzaki Y Cancer Metastasis Rev; 2005 Jun; 24(2):357-66. PubMed ID: 15986143 [TBL] [Abstract][Full Text] [Related]
24. Current immunotherapeutic strategies in malignant melanoma. Agostino NM; Ali A; Nair SG; Mosca PJ Surg Oncol Clin N Am; 2007 Oct; 16(4):945-73, xi. PubMed ID: 18022553 [TBL] [Abstract][Full Text] [Related]
25. [Immunotherapy for melanoma: how can tolerance be overcome?]. Robert C Ann Dermatol Venereol; 2001; 128(6-7):709-13. PubMed ID: 11460031 [No Abstract] [Full Text] [Related]
26. Self-recognition and tumor response to immunotherapy. Ernstoff MS J Clin Oncol; 2005 Sep; 23(25):5875-7. PubMed ID: 16087939 [No Abstract] [Full Text] [Related]
27. Evidence for antigenicity in human tumours with reference both to melanoma and acute leukemia. Fairley GH Proc R Soc Med; 1971 Oct; 64(10):1044. PubMed ID: 5145318 [No Abstract] [Full Text] [Related]
28. [Pro and con: Immunotherapy in acute leukemia. Arguments for immunotherapy]. Büchner T; Urbanitz D Internist (Berl); 1980 Jul; 21(7):362-6. PubMed ID: 7007269 [No Abstract] [Full Text] [Related]
29. [Pro and con: Immunotherapy in acute leukemia. Arguments against immunotherapy]. Hirschmann WD Internist (Berl); 1980 Jul; 21(7):367-70. PubMed ID: 7007270 [No Abstract] [Full Text] [Related]
30. Induction of peptide-specific immune response in patients with primary malignant melanoma of the esophagus after immunotherapy using dendritic cells pulsed with MAGE peptides. Ueda Y; Shimizu K; Itoh T; Fuji N; Naito K; Shiozaki A; Yamamoto Y; Shimizu T; Iwamoto A; Tamai H; Yamagishi H Jpn J Clin Oncol; 2007 Feb; 37(2):140-5. PubMed ID: 17255158 [TBL] [Abstract][Full Text] [Related]
32. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration. Andersen MH; Gehl J; Reker S; Pedersen LØ; Becker JC; Geertsen P; thor Straten P Semin Cancer Biol; 2003 Dec; 13(6):449-59. PubMed ID: 15001164 [TBL] [Abstract][Full Text] [Related]
33. The potential of melanoma antigen expression in cancer therapy. Gillespie AM; Coleman RE Cancer Treat Rev; 1999 Aug; 25(4):219-27. PubMed ID: 10448130 [TBL] [Abstract][Full Text] [Related]